Ulviyya EA and Bakhshiyev MM
Being a very common condition among the whole population of the world, often leading a life-threatening illness and having high risk and mortality rate, chronic heart failure (CHF) is also a major public health problem for the world. Our goal is to investigate what has been achieved in the treatment of CHF patients with a left ventricular ejection fraction (LVEF) <40% recent years. In recent years, it is revealed that BNP has been crucial in the pathogenesis of heart disease. Due to this reason, we tried to investigate the results of the complex medical treatment method performed with the combination of sacubitril/alsartan which angiotensin is receptor neprilysin inhibitor in CHF patients. We also investigated the device treatment methods used in the treatment of these patients, particularly the cardiac resynchronization therapy. Finally, we investigated the results of the complex medical treatment method performed with the combination of sacubitril/valsartan which is angiotensin receptor neprilysin inhibitor in comparison with the those of the cardiac resynchronization therapy.
இந்தக் கட்டுரையைப் பகிரவும்
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 